A 14-week, Multi-center Study of [S,S]-Reboxetine in Patients With Fibromyalgia.

• Drug: [S,S]-Reboxetine
  
  10 mg oral tablet once a day dosing
• Drug: Placebo
  
  0 mg oral tablet once a day dosing
• Drug: [S,S]-Reboxetine
  
  4 mg oral tablet once a day dosing
• Drug: [S,S]-Reboxetine
  
  8 mg oral tablet once a day dosing

• Experimental: 3
  
  Intervention: Drug: [S,S]-Reboxetine
• Sham Comparator: 4
  
  Intervention: Drug: Placebo
• Experimental: 1
  
  Intervention: Drug: [S,S]-Reboxetine
• Experimental: 2
  
  Intervention: Drug: [S,S]-Reboxetine

Inclusion Criteria:

• Male or female of any race, at least 18 years of age
• Patients must meet the ACR criteria for fibromyalgia (ie, widespread pain present for at least 3 months, and pain in at least 11 of 18 specific tender point sites)

Exclusion Criteria:

• Patients with other severe pain (eg, Diabetic Peripheral Neuropathy and PostHerpetic Neuralgia) that may confound assessment or self evaluation of the pain associated with fibromyalgia
• Patients with any autoimmune rheumatic disorder, non-focal rheumatic disease (other than fibromyalgia), active infection, or untreated endocrine disorder
• A current or recent diagnosis (last 6 months) or episode of major depressive disorder, dysthymia and/or uncontrolled depression
• History of mania, hypomania, other psychotic disorder, or current mood disorder with psychotic features